Antisense Therapeutics Phase II Trial Final Data Results (June 17, 2020)

Antisense Therapeutics recently announced that their Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne in non-ambulatory patients has met its primary endpoint, confirming the safety and tolerability of ATL1102 for advancement into a Phase IIb clinical trial. On June 17, 2020, Antisense joined PPMD for a webinar update on Antisense Therapeutics’ clinical program, as well as next steps in the upcoming Phase IIb trial.